New Implications of Patients' Sex in Today's Lung Cancer Management.
Jo RaskinAnnemiek SnoeckxAnnelies JanssensCharlotte De BondtReinier WenerMick van de WielJan P van MeerbeeckEvelien L J SmitsPublished in: Cancers (2022)
This paper describes where and how sex matters in today's management of lung cancer. We consecutively describe the differences between males and females in lung cancer demographics; sex-based differences in the immune system (including the poorer outcomes in women who are treated with immunotherapy but no chemotherapy); the presence of oncogenic drivers and the response to targeted therapies according to sex; the greater benefit women derive from lung cancer screening and why they get screened less; and finally, the barriers to smoking cessation that women experience. We conclude that sex is an important but often overlooked factor in modern-day thoracic oncology practice.
Keyphrases
- smoking cessation
- polycystic ovary syndrome
- pregnancy outcomes
- newly diagnosed
- end stage renal disease
- healthcare
- primary care
- palliative care
- type diabetes
- spinal cord
- transcription factor
- replacement therapy
- breast cancer risk
- cervical cancer screening
- pregnant women
- metabolic syndrome
- insulin resistance
- peritoneal dialysis
- skeletal muscle
- quality improvement
- rectal cancer